JSC Biochimpharm - სს ბიოქიმფარმი

What JSC Biochimpharm - სს ბიოქიმფარმი does

JSC Biochimpharm (სს ბიოქიმფარმი) is a Georgian biopharmaceutical company that develops, manufactures, and commercializes bacteriophage-based preparations as alternatives to antibiotics. The company operates from the historic Bacteriophage Institute in Tbilisi, established in 1934 by Giorgi Eliava and Felix d'Herelle, with a workforce of over 60 employees. Its core technology platform leverages naturally occurring bacteriophages — viruses that selectively target and destroy disease-causing bacteria without harming beneficial microflora — produced as sterile liquid dosage forms (vials, sprays) and capsules at an EU GMP certified facility.

The commercial product portfolio includes four primary brands: Phagyo (a liquid multi-component phage preparation for respiratory, urological, and gastrointestinal infections), Phagesti (a gastrointestinal phage formulation), TravelPhage (capsule form for travel-related infections), and PowerPhage (a veterinary antimicrobial product for livestock and poultry). The company holds two international patents and maintains a portfolio of 15 registered products.

Biochimpharm sells its phage preparations OTC through pharmacy networks, with distribution spanning more than 8,000 pharmacies across 9 countries. Go-to-market combines enterprise field sales targeting medical professionals (pediatricians, dentists, GPs) with channel partnerships through pharmacy distributors, and direct B2B relationships for veterinary and food-safety applications. Pricing is unit-based at consumer-OTC levels (e.g., Phagyo 4×20ml pack at $49.95). The company is privately held, with institutional support coming from EU/EBRD/Enterprise Georgia/GITA grants and co-financing rather than equity investment, and has stated a medium-term goal to expand distribution to 100+ countries with EU market entry targeted within 2–3 years.

Name

JSC Biochimpharm - სს ბიოქიმფარმი

Legal name

JSC Biochimpharm (სს ბიოქიმფარმი)

Website

https://biochimpharm.ge

Company type

Private

Founded year

1934

Operating status

Operating

Headcount range

11–50 employees

Short description

JSC Biochimpharm is a Georgian biopharmaceutical company that manufactures and sells bacteriophage-based antibacterial preparations as antibiotic alternatives, distributing through 8,000+ pharmacies across 9 countries and serving human and veterinary health markets.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Animal Food Manufacturing (3111)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Phage & Phage-Derived Microbiome Modulators (HLAAAFAF)

akta.pro secondary industries

Livestock & Production Animal Therapeutics (Rx) (HLAMAEAB), Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG), Veterinary Pharmacy, Vaccine & Biologics Services (AFAEANAK)

Keywords

• Bacteriophage therapy
• Pharmaceutical manufacturing
• Antibiotic alternatives
• Biopharmaceutical products
• Veterinary antimicrobials

Headquarters

HQ city

Tbilisi

HQ country

Georgia

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Sale of bacteriophage preparations (Phagyo, Phagesti, TravelPhage, PowerPhage) through pharmacy networks and direct B2B channels. Products are sold OTC (without prescription) in pharmacies across 9 countries.
2. Government and International Grants: Funding received from Georgian government agencies (Enterprise Georgia, GITA) and international organizations (EU, EBRD, FAO) for modernization projects and R&D activities. The company received support through loan interest co-financing programs.
3. Veterinary Product Sales: Sale of PowerPhage and other phage preparations for veterinary use in livestock, poultry, and fish farming as alternatives to antibiotics in agriculture.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

Core offering

JSC Biochimpharm develops, manufactures and sells bacteriophage (phage) based pharmaceutical preparations as a natural alternative to antibiotics for treating bacterial infections in humans and animals. Its human product line (Phagyo, Phagesti, TravelPhage) is sold OTC through pharmacy networks for respiratory, urinary, gastrointestinal and neonatal infections, while PowerPhage serves the veterinary and agricultural market as a replacement for antibiotics in livestock and poultry.

Product overview

JSC Biochimpharm (სს ბიოქიმფარმი) is a Georgian biopharmaceutical company specializing in bacteriophage-based antibacterial medications. The company offers a portfolio of phage therapy products targeting bacterial infections across human and veterinary applications. The core product line includes Phagyo® (liquid phage therapy for respiratory, urological, and gastrointestinal infections), Phagesti® (gastrointestinal phage formulation), TravelPhage™ (capsule form for travel-related infections), and PowerPhage (veterinary product for livestock and poultry). All products utilize naturally occurring bacteriophages as antimicrobial agents, positioning the company as a provider of antibiotic alternatives.

Differentiator

Problem solved

Functional benefit

Brands

• Phagyo®: A bacteriophage-based pharmaceutical product used for treatment and prophylaxis of bacterial purulent-inflammatory infections caused by Streptococcus, Staphylococcus, E.Coli, Pseudomonas aeruginosa, Proteus, and their combinations. Sold in 8000 pharmacies across nine countries.
• Phagesti®
• TravelPhage™
• PowerPhage

Products and services

• Phagyo® (Pyo Bacteriophagum Liquidum)
• Phagesti® (Bacteriophagum Intestinalis)

Named customers4 records

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core and minor.

• WHO EURO (World Health Organization Europe)coreStrategic or Co-development Partner · 1 January 2024Biochimpharm participated in WHO EURO and Global AMR R&D Hub international workshop on bacteriophages. The WHO EURO team visited Biochimpharm's phage factory after the workshop, highlighting recognition of the company's expertise.
• British EmbassyminorGTM or Marketing Partner · 1 January 2024Regional Export Director for Eastern Europe and Central Asia of the UK Department of Business and Trade, Sarah Chidgey, and Deputy Head of Mission visited the Biochimpharm phage factory to explore potential partnership opportunities.
• FAO (Food and Agriculture Organization)coreStrategic or Co-development Partner · 1 January 2023FAO Georgia under the ENPARD III program of the European Union partnered with Biochimpharm in the fight against antimicrobial resistance and development of phage technology for agricultural applications.
• European Business Association Georgia (EBA)minorGTM or Marketing Partner · 1 January 2022Biochimpharm participated as a partner at the EU-Georgia Business Forum 2022 organized by EBA, presenting their products and sharing experiences on EU pharmaceutical manufacturing standards compliance.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Emerging players

• Locus Biosciences: US clinical-stage company developing engineered phage ("crispr-phage") therapies for antibiotic-resistant infections. Comparable on phage-based antibacterial modality but with a more advanced clinical-stage Western orientation.
• Adaptive Phage Therapeutics: US clinical-stage phage-therapy company developing personalized phage treatments for antibiotic-resistant infections. Comparable on the human therapeutic side but positioned at the high-end clinical/Rx end of the market rather than OTC.
• ContraFect: US clinical-stage anti-infectives company developing lysin-based therapies (phage-derived enzymes) for resistant infections. Comparable mechanism (phage-derived antibacterial) and similar therapeutic target, but distinct modality.
• PhagePro: US startup developing targeted phage products for human bacterial infections. Comparable technology platform but earlier-stage and focused on a narrower therapeutic indication.

Direct peers

• Phagelux: China-based phage company focused on agricultural, food-safety, and animal-health applications. Direct peer on the veterinary/agricultural side of Biochimpharm's portfolio, with overlapping target customers in poultry and livestock.
• Eliava BioPreparations: Georgian phage-products company also descended from the historic Eliava Institute. Closest comparable peer — same city, same institutional heritage, same bacteriophage technology, with overlapping OTC distribution in similar CIS and regional markets.
• Intralytix: US-based commercial phage company producing FDA-cleared phage products for food safety (ListShield, SalmoFresh) and animal health. Direct peer on the agricultural/food-safety side of Biochimpharm's portfolio, particularly comparable to PowerPhage.
• Micreos: Netherlands-based phage company with PhageGuard food-safety products and a human-health pipeline (Gladskin). Comparable on phage-based antibacterial mechanism, regulatory maturity in EU, and dual human/agricultural exposure.

Broad incumbents

• Elanco Animal Health: Global animal-health company offering antibiotics, vaccines, and alternatives. Comparable on PowerPhage's veterinary customer base and a logical strategic acquirer given its stated focus on antibiotic alternatives in livestock.
• Zoetis: Largest global animal-health pharma company with broad portfolio including antibiotics and alternatives. Comparable on the PowerPhage veterinary customer base, and a likely acquirer or partner for scaling phage-based animal health.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/biochimpharm
• LinkedInlinkedin.com/company/biochimpharm
• Instagraminstagram.com/phagyo_

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about JSC Biochimpharm - სს ბიოქიმფარმი